Sujit Itty, MD
Ophthalmology · Phoenix, AZNPI 1699902577
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,717 of the $13,880 with a category attached, or 62.8%. 20 manufacturers reported payments, led by AbbVie at 42.6% of the total. Reporting peaked in 2022 at $6,842 and has fallen 84.4% since, to $1,065 in 2025. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $74.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Alimera Sciences, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$1K
- Genentech USA, Inc.$1K
- Astellas Pharma US Inc$402
- Novartis$400
- plus $2K from 14 others
Across 74 payments — averaging $2734.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Apellis Pharmaceuticals, Inc.$120K
- Genentech, Inc.$82K
What the payments were for
- Consulting fees$4,50032%
- Travel & lodging$6635%
- Food & beverage$8,71763%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $5,917 |
| Alimera Sciences, Inc. | 15 | $3,189 |
| Regeneron Healthcare Solutions, Inc. | 35 | $1,138 |
| Genentech USA, Inc. | 27 | $1,077 |
| Astellas Pharma US Inc | 13 | $402 |
| Novartis | 13 | $400 |
| Apellis Pharmaceuticals, Inc. | 8 | $396 |
| Bausch & Lomb Americas Inc. | 19 | $392 |
| Biogen | 8 | $300 |
| Dutch Ophthalmic, USA | 2 | $243 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $121 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| ANI Pharmaceuticals, Inc. | 3 | $58 |
| Coherus Oncology, Inc. | 2 | $37 |
| Alcon | 2 | $34 |
| Amgen | 1 | $24 |
| Harrow Eye, LLC | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $19 |
| Genentech, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$5,639
- Iluvien$2,882
- YUTIQ$2,237
- VABYSMO$263
- Syfovre$149
- EVA Ophthalmic Surgical System$125
- EYLEA HD$122
- STELLARIS PC$121
- EVA, combined machine$118
- BEOVU$106
How this compares
$13,880 in reported general payments places this provider in the 90th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 273 | $9,341 |
| LumiganBimatoprost | 17 | $6,994 |
| MoxifloxacinMoxifloxacin Hcl | 142 | $4,534 |
| Bromfenac Sodium | 14 | $3,937 |
| Loteprednol Etabonate | 19 | $2,673 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 124 | $2,146 |
| Ketorolac Tromethamine | 47 | $1,319 |
| Difluprednate | 13 | $1,124 |
| Brimonidine Tartrate | 63 | $1,065 |
| Atropine Sulfate | 19 | $820 |
| ValacyclovirValacyclovir Hcl | 20 | $462 |
| Ofloxacin | 37 | $378 |
| ErythromycinErythromycin Base | 17 | $216 |
| Timolol Maleate | 34 | $182 |
| Dorzolamide Hcl | 26 | $179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $5,917 | $6,99417 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $121 | $2,67319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Phoenix
- Pravin DugelPhoenix$176K
- Nishi ShahPhoenix$92K
- Karim JamalPhoenix$72K
- Benjamin HellerPhoenix$41K
- Neal PalejwalaPhoenix$33K
- Joshua DuncanPhoenix$30K
- Sachin MehtaPhoenix$23K
- Daniel ChurginPhoenix$15K
- John CasonPhoenix$14K
- Elahhe AfkhamnejadPhoenix$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.